Sangamo Therapeutics (SGMOQ) Receivables (2010 - 2025)

Sangamo Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $371000.0 for Q4 2025.

• On a quarterly basis, Receivables fell 25.8% year-over-year to $371000.0 in Q4 2025; TTM through Dec 2025 was $371000.0, a 25.8% decrease from a year earlier, with the FY2025 full-year figure at $371000.0, down 25.8% from the prior year.
• Receivables slipped to $371000.0 in Q4 2025 per SGMOQ's latest filing, from $523000.0 in the prior quarter.
• Across five years, Receivables topped out at $20.5 million in Q3 2024 and bottomed at $366000.0 in Q1 2025.
• The 5-year median for Receivables is $4.2 million (2022), against an average of $4.6 million.
• Across the five-year window, Receivables surged 1071.2% in 2024 and plunged 97.45% in 2025, its largest moves.
• Year by year, Receivables stood at $6.4 million in 2021, then slipped by 29.36% to $4.5 million in 2022, then plunged by 70.49% to $1.3 million in 2023, then tumbled by 62.29% to $500000.0 in 2024, then slipped by 25.8% to $371000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Receivables figures stand at $371000.0 (Q4 2025), $523000.0 (Q3 2025), and $372000.0 (Q2 2025).